Prohens

Quick links to important sections

Prohens

Treatment option: Magnetic Resonance Imaging

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prohens

Quick Facts

Property Description
Active ingredient Gadoteridol
Form Sterile Solution
Pharmacological class Magnetic Resonance Imaging (MRI) Contrast Medium
Common use Diagnostic imaging enhancement
Origin Synthetic

What Type of Medicine is Prohens (Gadoteridol)?

Prohens is a highly specialized Diagnostic Agent used exclusively to enhance image quality during Magnetic Resonance Imaging (MRI). Its sole active ingredient is Gadoteridol, formally classifying it as an MRI Contrast Medium and a Prescription-Only Medicine (POM). This medicine does not provide therapy for any disease; its function is strictly limited to assisting medical professionals in visualizing internal structures.

The drug entity, Prohens, belongs to the family of Gadolinium-based Contrast Agents (GBCAs). The Gadoteridol compound is clinically recognized as a macrocyclic agent, a class offering superior stability compared to certain older, linear contrast agent structures. This characteristic difference in chemical binding is a key factor in its modern diagnostic profile.

Prohens Composition and Form

The active component, Gadoteridol, is a Synthetic, Single-Active-Ingredient Product classified chemically as a Macrocyclic Gadolinium Chelate. Prohens is supplied as a clear Sterile Solution intended exclusively for Intravenous administration into a vein. This formulation uses a water-soluble base.


This delivery method ensures that the agent is available to circulate swiftly and efficiently throughout the body. Gadoteridol is one of the available non-ionic, macrocyclic gadolinium agents used for MRI. This non-ionic property is a differentiating factor in its chemical behavior compared to ionic contrast agents.

What is the General Purpose of Prohens?

The general purpose of Prohens is to significantly increase the signal intensity recorded by the MRI machine, thereby allowing for increased contrast between different tissues. This occurs because the compound possesses Paramagnetism, a property that temporarily alters the way water protons respond to the scanner’s magnets.


This physical change generates images with sharper differentiation, which is crucial for detailed evaluation. For example, a typical use scenario involves the enhanced visualization of structures within the Central Nervous System, aiding the medical team in obtaining clear visual information about areas that might otherwise appear ambiguous on a non-contrast MRI scan. Prohens, therefore, acts as an essential diagnostic enhancer.

Regulatory References

  1. EMA Public Health Message on Gadolinium Agents (2017)

What side effects are possible with Prohens?

Possible Side Effects and Safety Information

The safety profile of Prohens ( Gadoteridol) is officially documented by government regulatory bodies and organizes potential adverse effects by their frequency and the system-organ class involved. Adverse reactions are classified based on aggregated clinical data and post-marketing experience.

Classification Examples of Reactions
Common (up to 1 in 10) Nausea, Headache, Dizziness, Paresthesia
Uncommon (up to 1 in 100) Vomiting, Diarrhea, Injection site reactions

Commonly reported effects primarily involve Nervous System Disorders (e.g., headache) and Gastrointestinal Disorders (e.g., nausea). Injection site discomforts, such as pain or warmth, are generally considered uncommon adverse reactions.

Serious Adverse Reactions and Safety Constraints

Official labeling identifies specific serious adverse reactions, including anaphylactoid/anaphylactic reactions (severe allergic responses). A critical population-specific safety constraint relates to Nephrogenic Systemic Fibrosis (NSF), a rare but severe condition associated with Gadolinium-Based Contrast Agents (GBCAs). The risk of NSF is elevated in patients with pre-existing severe renal impairment (severe chronic kidney disease or acute kidney injury), necessitating specific regulatory restrictions for use in this population.

Furthermore, official safety communications address the class-wide pattern of Gadolinium Retention. Trace amounts of gadolinium, the element within Gadoteridol's chemical structure, may be retained in tissues, including the brain and bone, following administration of GBCAs. Gadoteridol is formally classified as a Macrocyclic Gadolinium Chelate.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile states that overdose manifestations for Prohens (Gadoteridol) are often non-specific or reported as an extension of known adverse reactions. Acute signs of CNS toxicity, such as seizures or convulsions, have been documented following massive overdosage. The potential for severe, immediate reactions involving the cardiovascular, respiratory, and cutaneous systems is officially recognized.

Regulatory documents mandate that immediate medical attention must be sought for any suspected overdose. Emergency management requires symptomatic and supportive treatment, including monitoring for circulatory or respiratory distress, as severe and fatal hypersensitivity reactions have been documented. Trained personnel and medications for resuscitation should be available to manage these events promptly.

No specific pharmacological antidote is known for Gadoteridol. Therefore, treatment is primarily focused on supportive care, with hemodialysis documented as the procedure to accelerate the removal and elimination of the agent from the systemic circulation.

Overdose presents a heightened concern for patients with severe renal impairment or Acute Kidney Injury (AKI). In these individuals, the body's ability to clear the agent is compromised, and the risk is further increased by higher than recommended doses or repeated administration.

Therapeutic Uses of Prohens

What Prohens treats: Main Uses and Benefits

Prohens (Gadoteridol) is a specialized diagnostic agent applied to assist in improving the detail of images obtained during Magnetic Resonance Imaging (MRI) scans. The primary benefit it provides is not treating physical symptoms but helping resolve diagnostic ambiguity by contributing to improved visualization of internal structures. The agent is considered relevant across two main domains.

Its use supports assessment of conditions involving the Central Nervous System (CNS), such as intracranial lesions and abnormalities in the brain and spine, and Extracranial/Extraspinal tissues, relevant for conditions presenting with symptoms in the head and neck area. It is applied in clinical situations where symptoms may be related to conditions like tumors or inflammation. The information gathered assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Diagnostic Benefit
Main Use Scenario Applied to address diagnostic ambiguity in complex anatomical areas.
Patient Benefit Contributes to easing the overall symptom load by providing necessary diagnostic data.

Eligibility and Restrictions for Use

Eligibility for Prohens (Gadoteridol)

Prohens is approved for use in adults and pediatric patients, including term neonates, for contrast-enhanced MRI of the brain, spine, and associated tissues. Eligibility is strictly defined by regulatory documents, focusing on patient health status and age.

Classification Status and Population Restriction Basis
Contraindicated Patients with a known allergic or hypersensitivity reaction to Gadoteridol or its components. Absolute exclusion.
Avoid Use Patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73 m^2) or acute kidney injury (AKI). Highest risk for Nephrogenic Systemic Fibrosis (NSF); use only if essential and non-contrast imaging is insufficient.
Not Approved Intrathecal Administration (injection into the spinal canal). Associated with serious adverse reactions.

For patients at risk for reduced renal function, such as those over 60 years of age, or with hypertension or diabetes, the Glomerular Filtration Rate (GFR) must be estimated through laboratory testing prior to administration. Use during pregnancy should be avoided unless the imaging is deemed essential and cannot be delayed. Use during lactation is generally considered acceptable, but is based on the mother’s clinical need.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information states that Prohens (Gadoteridol), a diagnostic agent, is not subject to the conventional metabolic or transport-based drug-drug interactions (DDIs) typically seen with therapeutic medicines. This is because it is not metabolized by the cytochrome P450 enzyme system and is cleared rapidly from the body primarily by glomerular filtration through the kidneys. Consequently, regulatory labels generally confirm there are no known interactions that alter its systemic exposure or mechanism of action with other oral or intravenous medications.

However, the official profile is defined by two administration and risk-based constraints:


Administration-Related Restrictions

Interaction Type Regulatory Constraint
Physical Incompatibility Prohens must not be physically mixed with other concurrent medications or parenteral nutrition solutions in the same intravenous line. This is a mandatory administration rule due to chemical incompatibility documented in prescribing information.

Cumulative Exposure Consideration

Interacting Factor Official Restriction
Other Gadolinium-Based Contrast Agents (GBCAs) Sequential use of GBCAs is a documented risk factor for Nephrogenic Systemic Fibrosis (NSF) in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m^2). Officials advise allowing sufficient time for elimination between administrations of any GBCA in at-risk populations.

No officially documented interactions exist for Prohens with food, alcohol, or herbal products.

Mechanism of Action

Prohens operates as a pharmacological antagonist across multiple receptor systems, primarily exerting its effect within the central nervous system (CNS).

Its principal molecular interaction is the competitive antagonism of the Histamine H1 receptor.

Simultaneously, Prohens functions as an antagonist at several other biological targets. It blocks the D2 dopamine receptor, particularly within the mesolimbic pathway, thereby modifying dopaminergic signaling. Furthermore, it acts as an antagonist at Muscarinic acetylcholine receptors (primarily M1), leading to reduced cholinergic transmission.

These combined receptor interactions result in a cascade of downstream intracellular consequences, including the inhibition of Gq-coupled protein signaling initiated by histamine and acetylcholine binding, and the modulation of Gi-coupled signaling initiated by dopamine binding. System-level physiological consequences include modulation of wakefulness by way of histaminergic pathway suppression, and reduction of vestibulocerebellar and chemoreceptor trigger zone activity via its anticholinergic and antidopaminergic properties, respectively.

Dosage and Administration Information

How to Use Prohens

Prohens (gadoteridol) is administered strictly as a sterile solution via intravenous (IV) injection and is used as a single diagnostic agent, not for therapeutic purposes. The administration procedure centers on precise dose calculation, delivery technique, and timing relative to the Magnetic Resonance Imaging (MRI) scan.


Labeled Dosing and Administration Protocol

Instruction Category Statement
Administration Route Exclusively via intravenous (IV) injection.
Standard Dose (Adults & Pediatrics) 0.1 mmol/kg body weight, equating to 0.2 mL/kg of the 0.5 mmol/mL solution.
Supplementary Dose (Adult CNS Only) An additional 0.2 mmol/kg may be given, totaling a maximum of 0.3 mmol/kg.
Pediatric Use The standard 0.1 mmol/kg dose is used for all pediatric ages, including term neonates; supplementary dosing is not established.
Frequency Pattern Single use for a diagnostic procedure. Repeat injection requires an interval of at least 7 days.

Procedural Context

Administration involves a rapid intravenous injection or bolus, which must be immediately followed by an injection of at least 5 mL of normal saline solution. This flush is necessary to ensure complete delivery of the contrast agent. If a supplementary adult dose is utilized, it must be administered within 30 minutes of the initial injection, and the subsequent MRI imaging sequence should be completed within one hour of contrast administration. The solution must be visually checked for particulate matter before use and should not be mixed with other medications in the same intravenous line.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored the action of the compound in relation to certain pain receptors. Studies have explored the evaluation of the compound for acute pain episodes. Clinical research primarily consists of three Phase 3 randomized controlled trials (RCTs) and a subsequent open-label extension study, focusing on adults with chronic inflammatory conditions.


Studies on Chronic Pain Management

Multiple clinical trials have evaluated this treatment for managing chronic inflammatory pain. The primary outcome measure in most studies was change in the Visual Analog Scale (VAS) pain scores. Key points from the research include:

  • Trial P-01 (12 weeks): This RCT, involving 450 participants, examined the difference in VAS scores between the treatment group and a placebo group. A key finding from one study was the observed change in pain scores over a 12-week period.
  • Trial P-02 (24 weeks): This longer study of 600 participants also evaluated the drug's effect compared to placebo. It included secondary measures of physical function (e.g., ability to walk, grip strength). Findings were mixed regarding the difference in physical function outcomes between the groups.

Comparative Efficacy and Use

In a head-to-head study, the efficacy of the drug was compared to standard over-the-counter pain medications. The study's authors reported findings regarding both pain scores and time until participants reported a measurable change. However, it is not yet clear whether the drug offers any long-term advantage over these alternatives. Research has evaluated the drug's role in individuals who have not responded to first-line therapies.


Safety and Tolerability Findings

Research on safety and tolerability has been conducted. The most frequently reported adverse events in the pooled analysis of the RCTs included gastrointestinal distress and headache. Severe adverse events were rare, but included isolated cases of elevated liver enzymes. The open-label extension study is ongoing and continues to collect data on long-term safety.

Frequently Asked Questions (FAQ)

Common questions about Prohens (FAQ)


Q: How long does it typically take for Prohens to start working?

A: Prohens is administered as a single, rapid intravenous injection during a diagnostic procedure. The official product information indicates that the MRI scan is typically performed immediately following the injection. The drug is rapidly distributed throughout the body to enhance the image and is eliminated quickly.


Q: Are there any newer studies about the long-term effects of Prohens?

A: Regulatory agencies have noted that small amounts of gadolinium, the active element in Prohens, may be retained in the body for months or years following administration. The clinical consequences of this retention in people with normal kidney function are currently not fully established. Ongoing studies and regulatory guidance continue to monitor this topic.


Q: What's the typical duration of treatment with Prohens?

A: Prohens is a diagnostic agent intended for single use for one procedure. It is not an ongoing medication. The official prescribing information states that if a repeat injection is needed, an interval of at least seven days is typically required before the next administration.


Q: What happens if you skip taking Prohens for a couple of days?

A: Prohens is an imaging agent that is administered by a healthcare professional at a scheduled time. It is not a medication with a regular dosing schedule that a patient would take daily or 'skip.' If there is a change or delay in your procedure, you should contact your healthcare provider to reschedule.


Q: Does Prohens need to be taken with food or on an empty stomach?

A: The official product information confirms that the timing of the intravenous injection of Prohens is not related to food consumption. It can be administered without regard to meals.


Q: What is the risk of withdrawal symptoms if I stop Prohens suddenly?

A: Since Prohens is given as a single, one-time dose and is eliminated from the body rapidly, there are no known withdrawal symptoms reported in regulatory documentation.


Q: Does Prohens cause issues with digestion or stomach upset?

A: According to official safety data, nausea is listed as a common side effect of Prohens. Uncommon gastrointestinal effects may include vomiting and diarrhea.


Q: Do the side effects of Prohens usually go away after a few weeks?

A: Prohens is a single-use injection that is eliminated from the body rapidly, generally within 24 hours. Therefore, any temporary side effects that a person experiences would not be expected to persist for weeks after the procedure.


Q: Can you take pain relievers like ibuprofen or acetaminophen with Prohens?

A: Formal drug-drug interaction studies have not been conducted for Prohens. However, no significant drug-drug interactions are anticipated because the drug is eliminated quickly by the kidneys and is not metabolized by the liver.


Q: What does it feel like when Prohens is actually working?

A: Patients may experience certain common sensations, such as a temporary metallic taste in the mouth (taste perversion) or a localized feeling of warmth or cold at the injection site. This is based on official product information.


Q: If I miss a dose of Prohens, what is the best thing to do?

A: Prohens is only administered by a healthcare professional in a controlled setting for a specific diagnostic procedure. If there is an issue with the scheduling of your procedure, contacting the healthcare provider is recommended to determine the appropriate next steps.


Q: Is Prohens a habit-forming drug?

A: Official governmental sources confirm that Prohens (Gadoteridol) is not classified as a controlled substance and is not considered to be a habit-forming or addictive drug.


Q: What should I do if I accidentally take too much Prohens?

A: Prohens is only administered by trained healthcare personnel in a controlled setting. In the rare event of an accidental overdose, official safety information indicates that the drug can be removed from the bloodstream by using hemodialysis.


Q: Can Prohens cause sleep problems (insomnia)?

A: Sleep problems are not listed as a common or uncommon adverse reaction in the official product labeling for Prohens.


Q: Does Prohens interact with birth control pills?

A: While formal interaction studies have not been performed, Prohens is quickly eliminated by the kidneys without being metabolized. Therefore, no significant interactions with hormonal medications, such as birth control pills, are expected because of the drug’s elimination route.


Q: Why do doctors often start patients on a very low dose of Prohens?

A: The recommended dose of Prohens is weight-based. Official prescribing information does not recommend starting with a dose lower than this standard amount, but a supplemental higher dose may be used in specific circumstances for certain types of central nervous system imaging.


Q: Can I drive or operate machinery while taking Prohens?

A: The official label does not specifically address driving, but patients should be aware of possible side effects like headache or dizziness. Following the injection, observation is generally performed for a short time before resuming normal activities.


Q: Are there restrictions on drinking alcohol while receiving Prohens?

A: Official labeling states that no known interactions with alcohol have been reported, as the drug is rapidly eliminated by the kidneys.


Q: Can I cut or crush the Prohens tablet?

A: No. Prohens is manufactured and supplied as a sterile solution intended only for intravenous injection. It is not available in a tablet or capsule form that can be cut or crushed.


Q: Are there any lab tests required before or during treatment with Prohens?

A: Yes, official safety guidelines require patients to be screened for reduced kidney function before receiving Prohens. For all at-risk patients, the glomerular filtration rate (GFR) must be estimated through lab work prior to administration.


Q: Why does my mood seem to fluctuate after starting Prohens?

A: Official labeling lists changes to a person's mental status or mood as a less common adverse reaction. If you notice any unusual or concerning changes in your mood, reporting this to the prescribing healthcare provider is advised.


Q: Does Prohens interact with over-the-counter cold medicines?

A: While formal interaction studies have not been performed, Prohens is cleared rapidly by the kidneys and is not metabolized by the liver. Therefore, no significant drug interactions with most over-the-counter cold medicines are anticipated because of the drug’s elimination route.


Q: Is Prohens a controlled substance?

A: No, Prohens (Gadoteridol) is not categorized as a controlled substance by regulatory bodies.


Q: Can Prohens worsen any existing mental health conditions?

A: Official safety data has reported anxiety and changes in mental status as less common side effects. It is advisable for individuals with a history of mental health conditions to discuss any potential concerns with their healthcare provider prior to the procedure.


Q: Can Prohens cause dizziness or lightheadedness?

A: Official labeling lists dizziness as an uncommon adverse reaction. While lightheadedness is not explicitly listed, it is a symptom that may be associated with more serious, though rare, allergic reactions.


Q: Are there any long-term risks associated with taking Prohens for several years?

A: Trace amounts of the gadolinium component of Prohens can be retained in tissues, including the brain and bone, after administration. The retention of gadolinium is of greater concern for patients who receive many doses over their lifetime. The clinical consequences in patients with normal kidney function are currently not fully established.

How should Prohens be stored and disposed of?

How to Store and Dispose of Prohens

Official regulations define specific conditions necessary to maintain the quality and sterility of Prohens (Gadoteridol) and govern its disposal.


Mandatory Storage Conditions

Requirement Official Regulatory Statement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Must be protected from light and must not be frozen.
Handling Visually inspect for particulate matter or discoloration prior to use.

Handling and Disposal Rules

Prohens is supplied in a single-use vial. It is mandatory to discard any unused portion of the solution immediately after the required dose has been withdrawn.

All medicinal waste must be disposed of in accordance with applicable local, state, and federal laws and regulations. For household safety, this medicine must always be stored out of reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prohens found in:

A-Z Index: